04:47 PM EDT, 09/11/2025 (MT Newswires) -- Dianthus Therapeutics ( DNTH ) said late Thursday it closed its upsized underwritten public offering, raising about $288 million in gross proceeds.

The offering consists of about 7.6 million common shares at $33 a piece, with underwriters exercising their option to buy an additional 1.1 million shares. Dianthus also issued pre-funded warrants for 1.1 million shares at $32.999 per warrant with a $0.001 exercise price.

The company plans to use the net proceeds to fund preclinical and clinical development programs, as well as working capital and general corporate purposes.